| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries
|
Pirenne, France
|
|
|
10 |
6 |
p. e468-e476
|
article
|
| 2 |
Appropriate use of sex and gender for diversity, equity, and inclusion in biomedical research
|
Bibb, Lorin A
|
|
|
10 |
6 |
p. e397-e398
|
article
|
| 3 |
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia
|
Curran, Emily
|
|
|
10 |
6 |
p. e393-e394
|
article
|
| 4 |
Celebrating blood donors amid advances in blood transfusion
|
The Lancet Haematology,
|
|
|
10 |
6 |
p. e389
|
article
|
| 5 |
Correction to Lancet Haematol 2023; 10: e250–60
|
|
|
|
10 |
6 |
p. e399
|
article
|
| 6 |
Correction to Lancet Haematol 2023; 10: e246–47
|
|
|
|
10 |
6 |
p. e399
|
article
|
| 7 |
Correction to Lancet Haematol 2023; 10: e419–32
|
|
|
|
10 |
6 |
p. e399
|
article
|
| 8 |
Correction to Lancet Haematol 2023; 10: e445–57
|
|
|
|
10 |
6 |
p. e399
|
article
|
| 9 |
Dealing with a changing medical landscape
|
Lucas, Tiffany L
|
|
|
10 |
6 |
p. e402
|
article
|
| 10 |
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial
|
Alexander, Sarah
|
|
|
10 |
6 |
p. e445-e457
|
article
|
| 11 |
Expanding therapeutic options for patients with primary immune thrombocytopenia
|
Lozano, Maria L
|
|
|
10 |
6 |
p. e390-e391
|
article
|
| 12 |
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility
|
Mills, Georgia S
|
|
|
10 |
6 |
p. e458-e467
|
article
|
| 13 |
Long-term sequelae after immunotherapeutic approaches in haematological malignancies—what do we know?
|
Escherich, Gabriele
|
|
|
10 |
6 |
p. e395-e396
|
article
|
| 14 |
Lucy Asamoah-Akuoko—sourcing blood amid varied obstacles
|
Cavanaugh, Ray
|
|
|
10 |
6 |
p. e403
|
article
|
| 15 |
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
|
Jabbour, Elias
|
|
|
10 |
6 |
p. e433-e444
|
article
|
| 16 |
Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia
|
Ghara, Niharendu
|
|
|
10 |
6 |
p. e391-e393
|
article
|
| 17 |
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group
|
Sato, Atsushi
|
|
|
10 |
6 |
p. e419-e432
|
article
|
| 18 |
Painting the place where procedures cause pain
|
Beitzke, Sabine
|
|
|
10 |
6 |
p. e404-e405
|
article
|
| 19 |
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
|
Liu, Xiaofan
|
|
|
10 |
6 |
p. e406-e418
|
article
|
| 20 |
49th annual meeting of the EBMT
|
del Pozo Martín, Yaiza
|
|
|
10 |
6 |
p. e400-e401
|
article
|
Journal description